Last reviewed · How we verify
PD-L1 peptide vaccine
PD-L1 peptide vaccine is a Biologic drug developed by Lene Meldgaard Knudsen. It is currently in Phase 1 development.
At a glance
| Generic name | PD-L1 peptide vaccine |
|---|---|
| Sponsor | Lene Meldgaard Knudsen |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Injection related reaction
- Rash maculo-papular
- Granuloma skin
- Nausea
- Arthralgia
- Pruritus
- Injection site reaction
- Diarrhoea
- Abdominal pain
- Dry skin
- Myalgia
Key clinical trials
- IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer (PHASE1)
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (PHASE1)
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (PHASE1)
- A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (PHASE1)
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (PHASE1)
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) (PHASE1)
- DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-L1 peptide vaccine CI brief — competitive landscape report
- PD-L1 peptide vaccine updates RSS · CI watch RSS
- Lene Meldgaard Knudsen portfolio CI
Frequently asked questions about PD-L1 peptide vaccine
What is PD-L1 peptide vaccine?
PD-L1 peptide vaccine is a Biologic drug developed by Lene Meldgaard Knudsen.
Who makes PD-L1 peptide vaccine?
PD-L1 peptide vaccine is developed by Lene Meldgaard Knudsen (see full Lene Meldgaard Knudsen pipeline at /company/lene-meldgaard-knudsen).
What development phase is PD-L1 peptide vaccine in?
PD-L1 peptide vaccine is in Phase 1.
What are the side effects of PD-L1 peptide vaccine?
Common side effects of PD-L1 peptide vaccine include Fatigue, Injection related reaction, Rash maculo-papular, Granuloma skin, Nausea, Arthralgia.
Related
- Manufacturer: Lene Meldgaard Knudsen — full pipeline
- Compare: PD-L1 peptide vaccine vs similar drugs
- Pricing: PD-L1 peptide vaccine cost, discount & access